Corpus Intelligence IC Memo — HEBER VALLEY HOSPITAL 2026-04-26 09:56 UTC
IC Memo — HEBER VALLEY HOSPITAL
Investment Committee Memorandum | UT | 19 beds | Grade B | EBITDA uplift $4.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HEBER VALLEY HOSPITAL

CCN 461307 | WASATCH, UT | 19 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

HEBER VALLEY HOSPITAL is a 19-bed suburban community hospital in WASATCH, UT with $55.8M in net patient revenue and a 8.4% operating margin. The hospital serves a payer mix of 23.9% Medicare, 6.1% Medicaid, and 70.0% commercial.

Thesis: Turnaround. Our ML models identify $4.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 8.4% to 15.8% (+736bps).

Net Revenue HCRIS$55.8M
Current EBITDA COMPUTED$4.7M
Operating Margin COMPUTED8.4%
Occupancy HCRIS29.4%
Revenue / Bed COMPUTED$2.9M
Net-to-Gross HCRIS54.3%
Distress Probability ML53.1%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
23
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 8.4% places it above the state median. Among 23 size-comparable peers (10-38 beds), the median margin is 1.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-38), prioritizing same-state peers. 23 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HEBER VALLEY HOSPITAL (Target)UT19$55.8M8.4%
GUNNISON VALLEY HOSPITALUT25$130.4M-6.4%
LAYTON HOSPITALUT37$121.1M9.5%
PARK CITY HOSPITALUT37$120.8M13.7%
UINTAH BASIN MEDICAL CENTERUT33$119.9M1.8%
MOUNTAIN WEST MEDICAL CENTERUT36$96.1M38.5%
SPANISH FORK HOSPITALUT16$65.3M0.5%
CENTRAL VALLEY MEDICAL CENTERUT25$60.7M4.3%
SEVIER VALLEY HOSPITALUT24$58.2M14.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.2M+210bp18mo
Cost to Collect4.5%2.5%$1.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$680K+122bp9mo
Clean Claim Rate88.0%96.0%$36K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.2M
Cost to Collect
$1.1M
Denial Rate Reduction
$1.1M
A/R Days Reduction
$680K
Clean Claim Rate
$36K
Total EBITDA Uplift$4.1M
Current EBITDA$4.7M
+ RCM Uplift+$4.1M
Pro Forma EBITDA$8.8M
Current Margin8.4%
Pro Forma Margin15.8%
WC Released (1x)$2.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$7.2M$72.0M9.99x58.5%
Base (11x exit)10.0x11.0x$7.2M$81.6M11.31x62.4%
Bull Case9.0x11.0x$6.5M$97.5M15.02x71.9%
Bull (12x exit)9.0x12.0x$6.5M$108.3M16.68x75.6%
Bear Case11.0x10.0x$7.9M$49.1M6.19x44.0%
Bear (11x exit)11.0x11.0x$7.9M$56.6M7.14x48.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 29.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 23 hospitals with 10-38 beds
  • Same-state prioritization (n=24)
  • Comp margins: P25=-7.2% / P50=1.8% / P75=9.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.